 |
PDBsum entry 1lvt
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Structural protein
|
PDB id
|
|
|
|
1lvt
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Variable domain structure of kappaiv human light chain len: high homology to the murine light chain mcpc603.
|
 |
|
Authors
|
 |
D.B.Huang,
C.H.Chang,
C.Ainsworth,
G.Johnson,
A.Solomon,
F.J.Stevens,
M.Schiffer.
|
 |
|
Ref.
|
 |
Mol Immunol, 1997,
34,
1291-1301.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
|
|
 |
 |
|
Abstract
|
 |
|
Antibody light chains of the kappa subgroup are the predominant light chain
component in human immune responses and are used almost exclusively in the
antibody repertoire of mice. Human kappa light chains comprise four subgroups.
To date, all crystallographic studies of human kappa light chains were carried
out on proteins of the kappaI subgroup. The light chain produced by multiple
myeloma patient Len. was of the kappaIV subgroup, it differed by only one
residue from the germ-line gene encoded protein. The variable domain fragment of
the light chain was crystallized from ammonium sulfate in space group C222(1).
The crystal structure was determined by molecular replacement and refined at
1.95 A resolution to an R-factor of 0.15. Protein Len has six additional
residues in its CDR1 segment compared to the kappaI proteins previously
characterized. The kappaIV variable domain, Len, differs in only 23 of 113
residues from murine kappa light chain McPC603. The RMS deviation upon
superimposing their alpha-carbons was 0.69 A. The CDR1 segment of the human and
murine variable domains have the same length and conformation although their
amino acid sequences differ in 5 out of 17 residues. Structural features were
identified that could account for the significantly higher stability of the
human kappaIV protein relative to its murine counterpart. This human kappaIV
light chain structure is the closest human homolog to a murine light chain and
can be expected to facilitate detailed structural comparisons necessary for
effective humanization of murine antibodies.
|
 |
|
|
|
|
 |